Vnitr Lek 2024, 70(7):452-456 | DOI: 10.36290/vnl.2024.088

Thromboprophylaxis of venous thromboembolism in internal medicine

Petr Dulíček
IV. interní hematologická klinika, FN a LF UK v Hradci Králové

Venous thromboembolism is still serious not only medical, but also social economic problem. For many decades we know about the risk of surgery for venous thromboembolism, but in hospitalized medical patients the awareness was underestimated. In the last 25 years the situation has been changed with the advance of scoring models, which can help us the identify individuals who need pharmacologic prophylaxis. The Padua prediction score is one of the most used. However, due to the amounts of risk factors, individual variability, it is not always easy to find correct recommendation not only from medical, but also economic point of view.

Keywords: immobilisation, thromboprophylaxis, venous thromboembolism.

Accepted: October 24, 2024; Published: November 14, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dulíček P. Thromboprophylaxis of venous thromboembolism in internal medicine. Vnitr Lek. 2024;70(7):452-456. doi: 10.36290/vnl.2024.088.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Nordström M, Lindblad B, Bergqvist D, et al. A prospective study of the incidence of deep - vein thrombosis within a defined urban population. J Intern Med. 1992; 232:155-160. Go to original source... Go to PubMed...
    2. Cohen AT, Agnelli G, Anderson FA et al. VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007; 98(04):756-764. Go to original source... Go to PubMed...
    3. Francis CW. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med. 2007;356:1438-1444. Go to original source... Go to PubMed...
    4. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341:793-800. Go to original source... Go to PubMed...
    5. Leizorovicz A, Cohen AT, Turpie AG et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874-879. Go to original source... Go to PubMed...
    6. Turpie AG. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. Am J Cardiol. 2000 Dec 28;86(12 B):48M-52M. doi: 10.1016/s0002-9149(00)01481. Go to original source...
    7. Hirmerová J. The prophylaxis against venous thromboembolic complications in internal medicine--the gap between theory and practice.Vnitr Lek. 2006 Apr;52(4):379-88.PMID: 16755994 Review. Czech.
    8. D Karetová, M Chochola, A Linhart. Prevention of thrombembolic disease in internal medicine. Čas Lek Cesk. 2006;145(5):353-357.
    9. Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost. 2005;94:750-759. Go to original source...
    10. Haas SK, Hach-Wunderle V, Mader F, et al. An evaluation of venous thromboembolic risk in acutely ill medical patients immobilized at home: the AT-HOME Study. Clin Appl Thromb Hemost. 2007;13:7-13. Go to original source... Go to PubMed...
    11. Chopard P, Spirk D, Bounameaux H. Identifying acutely ill medical patients requiring thromboprophylaxis. J Thromb Haemost. 2006;4:915-916. Go to original source... Go to PubMed...
    12. Kucher N, Koo S, Quiroz R et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352:969-977. Go to original source... Go to PubMed...
    13. Lecumberri R, Marque's M, Di'az-Navarlaz MT, et al. Maintained effectiveness of an electronic alert system to prevent venous thromboembolism among hospitalized patients. Thromb Haemost. 2008;100:699-704. Go to original source... Go to PubMed...
    14. Barbar S, Noventa F, Rossetto V. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score J Thromb Haemost. 2010 Nov;8(11):2450-7. doi: 10.1111/j.1538-7836.2010.04044.x. Go to original source... Go to PubMed...
    15. Modrá kniha České onkologické společnosti, Aktualizace: 30, Brno, 2024, kapitola 38.
    16. Sebaaly J, Covert K. Enoxaparin Dosing at Extremes of Weight: Literature Review and Dosing Recommendations. Ann Pharmacother 2018 Sep;52(9):898-909.doi: 10.1177/1060028018768449. Epub 2018 Mar 28. Go to original source... Go to PubMed...
    17. Rostas JW, Brevard SB, Ahmed N. et al. Standard dosing of enoxaparin for venous thromboembolism prophylaxis is not sufficient for most patients within a trauma intensive care unit. Am Surg. 2015;81(09):889-892. Go to original source...
    18. Bickford A, Majercik S, Bledsoe J, et al. Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient. Am J Surg. 2013;206(06):847-851,851-852. Go to original source... Go to PubMed...
    19. Freeman A, Horner T, Pendleton RC, et al. Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. Am J Hematol. 2012;87(07):740-743. Go to original source... Go to PubMed...
    20. Rondina MT, Wheeler M, Rodgers GM, et al. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thromb Res. 2010;125(03)220-223. Go to original source... Go to PubMed...
    21. Abildgaard A, Madsen SA, Hvas AM. Dosage of Anticoagulants in Obesity: Recommendations Based on a Systematic Review Semin Thromb Hemost. 2020;46(08):932-969. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.